Table 1.
Demographic and clinical characteristics of study participants.
| Subgroups of RVO | |||||
|---|---|---|---|---|---|
| Clinical variables | Control | RVO | CRVO | BRVO | p values |
| N = 19 | N = 20 | N = 6 | N = 14 | BRVO vs. CRVO | |
| Age (mean ± SD) years | 66.63 ± 5.29 | 59.55 ± 11.44 *, a | 60.17 ± 11.04 | 59.29 ± 12.00 *, c | 1.000 |
| Male (%)b | 52.6 | 60.00 | 16.67 | 50.00 | 0.163 |
| Hypertension (%)b | 42.10 | 55.00 | 16.66 | 71.43 | 0.111 |
| Diabetes (%)b | 10.50 | 10.00 | 16.66 | 7.14 | 0.515 |
| Smoking (%)b | 26.30 | 15.00 | 16.66 | 14.29 | 0.891 |
| BMI (mean ± SD) kg/m2 | 22.13 ± 3.58 | 24.83 ± 3.21 | 23.7 ± 2.62 | 25.32 ± 3.40 | 1.00 |
| BCVA (mean ± SD) | 0.93 ± 0.85 | 0.92 ± 0.28 | 0.97 ± 0.24 | 0.90 ± 0.31 | 1.000 |
| RVO duration (≤ 1-month) (%)b | \ | 50 | 50 | 50 | 1.000 |
| CRT (mean ± SD) μm | 222.22 ± 25.91 | 588.85 ± 221.26 **, a | 660.50 ± 215.33 **, c | 558.14 ± 224.35 **, c | 0.56 |
| FAZ (mean ± SD) mm2 | \ | 0.24 ± 0.14 | 0.23 ± 0.13 | 0.24 ± 0.15 | 0.966 |
| PERIM (mean ± SD) mm | \ | 1.93 ± 0.57 | 2.05 ± 0.58 | 1.89 ± 0.58 | 0.582 |
| ILM-IPL (mean ± SD) | \ | 125.82 ± 96.88 | 169.11 ± 121.79 | 107.26 ± 82.33 | 0.199 |
| SVD (mean ± SD) | \ | 44.75 ± 3.77 | 44.57 ± 3.21 | 44.82 ± 4.09 | 0.894 |
| DVD (mean ± SD) | \ | 44.63 ± 3.23 | 45.91 ± 2.68 | 44.08 ± 3.37 | 0.255 |
aIndependent sample t-test, between controls and RVO patients; bChi-square test; cOne-way ANOVA test analyzed controls, CRVO, and BRVO patients. *p < 0.05; **p < 0.01. Bold indicating p value was statistically significant. RVO, retinal vein occlusion; BRVO, branch retinal vein occlusion; CRVO, central retinal vein occlusion; BMI, body mass index; BCVA, best corrected visual acuity (expressed as LogMAR); CRT, central retinal thickness; FAZ, foveal avascular zone; PERIM, perimeter of fovea; ILM-IPL, inner limiting membrane-inner plexiform layer; SVD, superficial vessel density; and DVD, deep vessel density.